Cepheid gets CLIA waiver for Xpert Xpress MVP
Jan. 19, 2024—Cepheid announced it has received FDA clearance with a CLIA waiver for the Xpert Xpress MVP, a multiplex vaginal panel that can now be performed in near-patient settings.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
BioMérieux acquires software company Lumed
Jan. 11, 2024—BioMérieux has acquired the entire share capital of software company Lumed, increasing its stake from 16 to 100 percent.
Horiba Medical launches next-gen HELO hematology solution
Jan. 9, 2024—Horiba Medical has launched the CE-IVDR-approved HELO 2.0 high-throughput automated hematology platform.
New chapter in digital pathology
Jan. 8, 2024—Advancements in whole slide imaging, integration of AI, and global collaboration networks are three areas the new president of the Digital Pathology Association highlighted in his first communication with DPA members this year.
Sekisui, Aptitude partner to provide POC COVID test
Jan. 4, 2024—Sekisui Diagnostics formalized an exclusive distribution agreement with Aptitude Medical Systems to sell the Aptitude Metrix COVID-19 test in the United States.
FormaPath, UB CAT announce clinical R&D collaboration
Jan. 4, 2024—FormaPath and the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT) announced their collaboration to further test and develop FormaPath’s AdiPress, an automated lymph node dissection device. FormaPath and John Tomaszewski, MD, SUNY distinguished professor and the Peter A. Nickerson, PhD, Professor and Chair, Department of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences at UB, will use AdiPress to conduct comprehensive analyses of tissue specimens to identify
Roche to acquire LumiraDx’s POC technology
Jan. 2, 2024—Roche announced it has entered into a definitive agreement to acquire LumiraDx’s point-of-care technology platform business, which offers a range of immunoassay and clinical chemistry tests that can be stored at room temperature.
Tosoh G8 now connects to Sysmex XN-9000, XN-9100 systems
Dec. 27, 2023—Tosoh Bioscience has entered into an agreement with Sysmex America in which its HLC-723G8 automated glycohemoglobin analyzers can now be connected to Sysmex XN-9000 and XN-9100 automated hematology systems in the United States, Latin America, and Canada.
FDA clears QuidelOrtho Savanna platform, HSV 1+2/VZV assay
Dec. 21, 2023—QuidelOrtho has received FDA 510(k) clearance for its Savanna PCR platform and Savanna HSV 1+2/VZV in vitro diagnostic test for the detection and differentiation of herpes simplex virus types 1 and 2 and varicella zoster virus nucleic acids isolated and purified from swabs obtained from cutaneous or mucocutaneous lesion specimens from symptomatic patients.
Corista DP3 platform gets CE IVD mark
Dec. 14, 2023—Corista announced today that its DP3 platform has been certified with the CE in vitro diagnostic mark for routine diagnosis in the European Union and United Kingdom.